| Prev Close | 136.42 |
| Day Low/High | 133.03 / 142.80 |
| 52 Wk Low/High | 101.36 / 147.87 |
| Avg Volume | 4.74M |
Eli Lilly & Co. (LLY)
141.50
5.10
3.70
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 957.04M |
| Market Cap | 130.56B |
| EPS | 5.00 |
| P/E Ratio | 27.50 |
| Div & Yield | 2.96 (1.93%) |
Wall Street Continues to See Opportunity in Eli Lilly
LLY's stock slide after earnings might present a buying opportunity.
2 Groups to Watch as the Midterm Election Unfolds: Cannabis and Drug Stocks
A bunch of pot stocks are in play on Tuesday -- for a reason.
Eli Lilly Offers Healthy Outlook to Kick Off November
The giant drugmaker raised its profit guidance for all of 2018 after its third-quarter results beat expectations.
Eli Lilly Could Hit New Highs, but Market Weakness Could Mute Gains
It shouldn't hurt that the drugmaker beat third-quarter estimates and raised its profit guidance for all of 2018.
Jim Cramer: Keep an Eye on the Insiders Who Are Buying
Insiders buy for only one reason -- to make money.
Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken
Once the safest stocks in the book, the big-cap drug companies are now toxic.
Eli Lilly Is Just Taking a Normal Pause
LLY has made a good run this year and now looks like it will correct a bit.
Jim Cramer: Avoid the Naked CEOs When the Tide Goes Out
There is clear divergence between the best and the worst performers in each sector this earnings season.
Ford May Look Like a Value but It's Currently Dead Money
There are concerns that interest rates may start to impact new car sales.
Constellation Brands Is a Bright Star on a Down Day
With STZ's earnings beat and the potential of the CGC investment, investors are willing to pay a premium.
Major Shifts in Investment Themes, Higher Interest Rates Shake up the Market
This is a market driven by macro matters and is not as favorable to stock pickers right now.
Intel Regains Its Leadership Position in the Semiconductor Sector
The stock still needs to do more work to be convincing.
Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter
Straying from these names could land you in quicksand as the 4th quarter begins.
Alphabet Before Congress, Fed Decision Make for an Interesting Day
Traders are likely remembering what Facebook stock did when Mark Zuckerberg testified before Congress.
A Brief Bird's Eye View of Fresh IPO Elanco Animal Health
The limited technical data for the recent Eli Lilly spinoff indicate buyers came in early and appear to be holding.
Eli Lilly Breaks Out of a Large Consolidation Pattern, Further Gains Ahead
The weekly breakout is pretty impressive on the charts, so let's take a look.
Jim Cramer: 4 Pet-Related Stocks That Are Top Dog
The humanization of pets theme is driving outstanding earnings and share price growth for these 4 names.
Jim Cramer: How to Pick Stocks When the Market Is Flying Blind
This market clearly has no clue what to buy, with strong GDP growth but challenging trade dynamics and the Facebook and Twitter bombs last week.
The Race to Cure Alzheimer's is On: These Are the Forerunners
Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.
Jim Cramer: We've Got an Extremist Market
Don't buy up when there's nothing but rampant pin action.
3 Ways to Play Facebook Ahead of Wednesday's Earnings
Here are some options strategies for this FANG name into tomorrow's report.
Latest Reasons to Avoid Alzheimer's Plays
Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.
Jim Cramer: Many Reasons Why a Stock Market You Think Should Go Down, Doesn't
You should be thinking positively these days if your stock has had a run or even if it hasn't as a preponderance of good things is liable to happen.
Closing Bell: LIVE MARKETS BLOG
All three major averages closed Thursday's session in positive territory.
Feels Like the Semis Are Skating on Thin Ice: Market Recon
Forward looking valuations, except for Nvidia, are very low.
Here's My Take on Biotech Stocks
I think M&A activity will pick up markedly going forward across the industry.
